|
|
| | AZTSBAWJROLRIQ-LESCRADOSA-N Basic information |
| Product Name: | AZTSBAWJROLRIQ-LESCRADOSA-N | | Synonyms: | AZTSBAWJROLRIQ-LESCRADOSA-N;(3R,4S,5S)-tert-Butyl 4-(((benzyloxy)carbonyl)amino)-3-hydroxy-5-methylheptanoate;Heptanoic acid, 3-hydroxy-5-methyl-4-[[(phenylmethoxy)carbonyl]amino]-, 1,1-dimethylethyl ester, [3R-(3R*,4S*,5S*)]- (9CI);tert-butyl (3R,4S,5S)-4-(((benzyloxy)carbonyl)amino)-3-hydroxy-5-methylheptanoate;tert-butyl (3R,4S,5S)-3-hydroxy-5-methyl-4-(phenylmethoxycarbonylamino)heptanoate;Monomethyl auristatin E intermediate-7 | | CAS: | 135383-55-0 | | MF: | C20H31NO5 | | MW: | 365.46 | | EINECS: | | | Product Categories: | | | Mol File: | 135383-55-0.mol |  |
| | AZTSBAWJROLRIQ-LESCRADOSA-N Chemical Properties |
| form | Solid | | color | White to off-white |
| | AZTSBAWJROLRIQ-LESCRADOSA-N Usage And Synthesis |
| Uses | Monomethyl auristatin E intermediate-7 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs)[1]. | | References | [1] Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87. DOI:10.1158/0008-5472.CAN-14-1931 |
| | AZTSBAWJROLRIQ-LESCRADOSA-N Preparation Products And Raw materials |
|